General Electric
http://www.ge.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From General Electric
Oyster Point Prepares Major Push For New Dry Eye Drug
Execs told Scrip they hope to get Tyrvaya (varenicline) onto formularies and aim for pricing that would make its nasal spray competitive with Restasis and Xiidra.
Q3 Review: Editor’s Picks Of Scrip's Top Stories
From the latest COVID-19 advances to the emergence of game changer for heart failure, Scrip’s editor in chief Eleanor Malone reviews the big stories of the past three months. Safety issues around JAK inhibitors and AAV vector-based gene therapy were also to the fore, while biopharma financing continued apace.
UCB Frustrated By FDA Failure To Inspect Facility For Psoriasis Drug
The Belgian group is the latest to be hit by the FDA's difficulties in address the growing backlog of facility inspections, leaving bimekizumab in limbo in the US, despite having just been approved as Bimzelx in Europe.
First-Of Kind BMS Drugs Among Myriad New Filings In EU
Marketing applications for 10 new drugs have been added to the latest list of products under review by the European Medicines Agency.
Company Information
- Industry
- Diversified
- Medical Devices
- Other Names / Subsidiaries
-
- Amersham
- Clarient Inc.
- Asymptote Limited
- GE Healthcare
- GE Medical Systems LLC
- Monica Healthcare
- Novia Strategies
- Vital Signs.
- Xcellerex
- U-Systems
- Zionexa SAS